May. 11 at 6:56 PM
The team at B2i Digital welcomes Precipio, Inc. - Nasdaq:
$PRPO as a new Featured Company. A dedicated company profile will be available soon at https://b2idigital.com/featured-companies.
Precipio is a healthcare biotechnology company focused on addressing cancer misdiagnosis. The company pairs a clinical pathology laboratory with a proprietary diagnostics product division.
The clinical lab generates recurring revenue and gives the product team direct access to patient samples and physician feedback, supporting the development of new assays at lower incremental cost and on faster development timelines.
Precipio’s commercial products focus on blood cancer diagnostics, where misdiagnosis rates have been reported as high as 28% and molecular turnaround times can commonly run 10 to 15 days. Its portfolio includes HemeScreen, a targeted molecular panel platform, and IV-Cell, a universal cell culture media for cytogenetics. The company’s Bloodhound BCR-ABL1 assay was recently the subject of a joint publication with Memorial Sloan Kettering Cancer Center. National distribution is supported by agreements with McKesson, Fisher Healthcare, Cardinal Health, and Medline.
For the year ended December 31, 2025, Precipio reported net sales of
$24.0 million, up 30% from 2024 on case volume of 15,470. Gross margin expanded to 45% from 41%, and operating activities generated
$0.7 million in cash.
Precipio is led by Ilan Danieli, CEO; Matt Gage, CFO; Dr. Ayman Mohamad, CTO; A. Zaki Sabet, COO; Miri Chiko-Radomski, CPO and Legal Counsel; and Stephen Miller, CCO.
To learn more, visit https://www.precipiodx.com. For investor inquiries, contact
[email protected] or +1-203-787-7888 Ext. 523.
Discover more Featured Companies, Featured Experts, and Featured Conferences at https://b2idigital.com. Disclosure: B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security.
